While the U.S. spends twice as much on cancer care as the average high-income country, its cancer mortality rates are only slightly better than average, according to a new analysis by researchers at Yale University and Vassar College.
The results were published May 27 in JAMA Health Forum.
“There is a common perception that the U.S. offers the most advanced cancer care in the world,” said lead author Ryan Chow, an M.D./Ph.D. student at Yale. “Our system is touted for developing new treatments and getting them to patients more quickly than other countries. We were curious whether the substantial U.S. investment on cancer care is indeed associated with better cancer outcomes.”
